ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Chrysin mitigates ciprofloxacin-induced nephrotoxicity: associations with notch/HES1 signaling, inflammation, and a ferroptosis-related molecular signature.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ciprofloxacin beyond antibacterial therapy: pharmacological mechanisms, anticancer activity, and translational limitations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ciprofloxacin (CIP) is a widely used antibiotic frequently associated with dose-limiting nephrotoxicity. Chrysin (CHR), a natural flavonoid, possesses significant cytoprotective properties, yet its specific role in mitigating CIP-induced kidney injury remains underexplored. This study investigates the comprehensive nephroprotective mechanisms of CHR against CIP toxicity in rats. Male Wistar rats received CIP (100 mg/kg/day, i.p.) with or without CHR (50 mg/kg/day, p.o.) for 8 consecutive days. Results showed that CIP administration compromised renal function (urea, creatinine) and structural integrity, while markedly altering tubular injury markers (KIM-1, AQP-1). Biochemical and molecular analyses revealed that CIP disrupted cellular redox balance (MDA, GSH, SOD, CAT, GPx) and triggered a robust inflammatory response (NF-κB, TNF-α, IL-17A). Furthermore, CIP exposure engaged distinct cell death mechanisms, including intrinsic apoptosis (Bax, Bcl-2, Caspase-3) and ferroptosis (GPX4, TfR1, PTGS2). A novel finding was the activation of the Notch signaling pathway (Notch, HES1) in renal tissue. CHR co-treatment significantly attenuated these pathological changes, restoring renal function and histology, re-establishing antioxidant defenses, and suppressing inflammatory and apoptotic signaling and normalizing ferroptosis-related gene expression changes. In conclusion, CHR confers robust nephroprotection by targeting the inflammation-ferroptosis-apoptosis axis and modulating Notch signaling, positioning it as a promising adjuvant to mitigate CIP-induced renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.